Ohr Pharmaceutical announced positive top-line interim results for its double-masked, placebo-controlled Phase II clinical trial of Squalamine eye drops in patients with wet age-related macular degeneration. The data demonstrated a positive benefit in visual function across multiple clinically relevant endpoints, including a mean change in visual acuity at the end of study visit for the interim analysis group of plus 10.4 letters with Squalamine eye drops plus Lucentis PRN versus plus 6.3 letters in the placebo eye drops plus Lucentis PRN arm. The visual acuity improvements were seen as early as four weeks and the relative difference in visual acuity between the two treatment arms continued to increase throughout the study. In the interim analysis, there were no significant differences in the frequency of Lucentis PRN injections, which was the primary endpoint of the study. The company plans to present the full data from this interim analysis at an ophthalmology conference in the 2H14, with final clinical trial data expected in the 1Q15.